Fenofibrate - AbbVie/Fournier

Drug Profile

Fenofibrate - AbbVie/Fournier

Alternative Names: Lipanthyl; TriCor

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Fournier Pharma
  • Class Antihyperlipidaemics; Benzophenones; Butyric acids; Fibric acid derivatives; Propionates; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypercholesterolaemia; Hypertriglyceridaemia

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 20 Nov 2012 Generic equivalent available in USA
  • 26 Feb 2009 Additional efficacy data from the FIELD trial in Type 2 diabetes mellitus released by Solvay
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top